RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $51 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has reiterated his 'Outperform' rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintained a price target of $51.
July 17, 2023 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xenon Pharmaceuticals' stock may see positive movement as RBC Capital maintains its 'Outperform' rating and $51 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of an 'Outperform' rating and a maintained price target by a reputable firm like RBC Capital is likely to boost investor confidence in Xenon Pharmaceuticals, potentially leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100